THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Yes, Sir. The custom duty concession has been given on the following intermediates for the production of Amplicillin Trihydrate;

(i) Hexamethyl Disilazone

(ii) Trimethyl Clorosilane

(iii) Dimethyl Acetamide

(iv) 2, 6 Lutidine.

(c) and (d) Impact of duty concession will also affect Ampicillin Sodium which will be taken into account in price fixation/revision.

(e) Yes Sir.

(f) The information regarding production during last 2 years will be collected and laid on the Table of the House.

(g) and (h) BICP conduct the cost-cum-technical study on the basis of cost data submitted by the manufacturers convering major production.

Loan licence arrangements

679. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 779 given in the Rajya Sabha on the 25th July, 1991 and state:

(a) whether it is a fact that copies of all the loan licence arrangements are made available to Government by the State Drug authorities;

(b) whether it is also a fact that number of products are got produced under loan licence arrangements by M/s. Glaxo, Hoechst, Fairdeal and German Remedies without any industrial licence;

(c) whether it is also a fact that details are being withheld to shield these companies;

(d) whether it is a fact that these companies are minting crores of rupees without any investment and also deriving the benefits of price control order, ratio parameters and other policy provisions not applicable to small scale sector; and

(e) if so, what are the details available with Government on this issue and what steps have been taken to monitor such activities which is misleading to consumer?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Loan licences are given under the Drugs & Cosmetics Act by the State Drug Controllers. There is no provision in this Act that copies of such licences be made available to this Department.

(b) The companies concerned would be asked to give information in this regard.

(c) No, Sir.

(d) There is no specific information in this regard.

(e) Does not arise.

Omissions and Commissions in findings of BICP

680. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1657 given in Rajya Sabha on the 1st August 1991 and state:

(a) whether it is a fact that recommendations of BICP in respect of price of Benzathine Penicilline, Vitamin-C, Sulphamoxole, Ethambutol, Phedrine HCL were full of omissions and commissions;

(b) what was the price recommended by BICP for each and what was the price approved after examination by Government;

(c) what are the areas where discrepancies were found and what are the details in each cas where classification was sought from BICP;

(d) whether it is a fact that Government did not agree to those clarifications and found those as errors and omissions;

(e) if so,, what are the details of those discrepancies which have come to the notice of Government;

(f) whether it is also a fact that all the BICP findings are known to the producers even before those are submitted to Government; and

(g) if so, what steps have been taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (g) The prices of scheduled bulk drugs are fixed by this Department as per due examination of the recommendations made by BICP on their cost-cum-technical studies. The fixed prices are notified in the official gazette from time to time. Where necessary cases, clarifications are sought from BICP on their recommendations before arriving at a final decision. The recommendations contained in the cost-cum-technical study of BICP are of confidential nature and therefore it is not in public interest to disclose them.

Norms for determining value addition regarding drug

681. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 778 given in the Rajya Sabha on the 25th July, 1991 and state:

(a) what are the prescribed norms followed by Government for determing the value addition in the case of drugs and pesticides and when they were prescribed and by whom;

(b) whether it is a fact that these norms differ from the norms followed by CCI&E for determining the value added;

(c) if so, the details thereof;

(d) what steps have been taken to rectify the same and what are the reasons for allowing these differences to continue;

(e) whether it is also a fact that those differences have lead to value substraction rather than value addition in exports; and

(f) if so, the instances which have come to light?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The information is being collected in consultation with Ministry of Finance and will be laid on the Table of House.

Formulation prices of M/s. Rhone Poulenc and M/s. Bayer

682. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 777 given in the Rajya Sabha on the 25th July, 1991 and state:

(a) whether it is a fact that formulation prices of M/s. Rhone Poulenc and M/s. Beyer are based on Phenobarbitone price of Rs. 748 per kg. plus 6 per cent incidentals;

(b) if so, when the formulation prices were fixed;

(c) whether it is also a fact that these companies have been importing phenobarbitone regularly;

(d) what was the quantity imported by each of them during the last three years, year-wise;

(e) whether it is a fact that due to huge difference between indigenous and landed price these companies have made benefit of crore of Rupees on account of formulation prices based on indigenous price of bulk drugs; and

(f) what steps have been taken to do justice to public and fix the price on proportionate basis and what action is proposed to be taken against those responsible for such state of affairs?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b), (e) to (f) Do not arise.

(c) to (d) Company wise imports are not monitored. However, information regarding quantum of imports of this drug during the last 3 years, period ending 1989-90, has already been given in reply to Rajya Sabha Unstarred Question No. 777 answered on 25th July, 1991.